Novus Biologicals products are now on bio-techne.com

Recombinant Human cIAP-1 (HIAP-2) Protein, CF

Images

 
There are currently no images for cIAP-1/HIAP-2 (818-IA).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Inhibition Activity
Format
Carrier-Free

Order Details

Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human cIAP-1 (HIAP-2) Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit DEVD-AFC cleavage activity in cell extracts activated by addition of cytochrome c and dATP. The IC50 for this effect is 25-1000 nM.
Optimal dilutions should be determined by each laboratory for each application.
Source
E. coli-derived human cIAP-1/HIAP-2 protein
ATVID 10-His tag SIEGRA Human cIAP-1
(His2-Ser618)
Accession # Q13490
N-terminus C-terminus
Accession #
N-terminal Sequence
Ala
Protein/Peptide Type
Recombinant Enzymes
Gene
BIRC2
Purity
>85%, by SDS-PAGE under reducing conditions and visualized by silver stain

Applications/Dilutions

Dilutions
  • Inhibition Activity
Theoretical MW
72 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
68 kDa, reducing conditions
Publications
Read Publications using
818-IA in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
Buffer
Supplied as a 0.2 μm filtered solution in HEPES, NaCl, DTT and Glycerol.
Purity
>85%, by SDS-PAGE under reducing conditions and visualized by silver stain
Assay Procedure
  • Jurkat A3 wild type cell extracts (see supplementary methods for preparation)
  • Extraction Buffer: 50 mM HEPES, 10 mM KCl, 5 mM EGTA, 1 mM MgCl2, 0.2% CHAPS, 0.2 mM DTT, pH 7.5
  • Assay Buffer: 10 mM HEPES, 0.5 mM EGTA, 5 mM DTT, 10% Glycerol, pH 7.5
  • Recombinant Human cIAP‑1/HIAP‑2 (rhcIAP-1) (Catalog # 818-IA)
  • Cytochrome C, Bovine heart (Sigma, Catalog # C3131), 2 mg/mL stock in deionized water
  • dATP (Sigma, Catalog # D6500), 10 mM stock adjusted to pH 7.5
  • Cell Extracts from Jurkat A3 wild type cells (see above protocol)
  • Substrate: Ac-Asp-Glu-Val-Asp-AFC (DEVD-AFC) (MP Biomendicals, Catalog # AFC138), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
Note: All reagents and assay components should be kept on ice until use.
  1. Thaw cell extracts and centrifuge in a microcentrifuge at 14,000 rpms for 5 minutes at 4 °C. Transfer supernatants to chilled tubes and use within 1 hour.
  2. Prepare a curve of rhcIAP-1 (MW: 72,000 Da) in Extraction Buffer. Make the following serial dilutions: 5000, 2000, 1000, 500, 250, 125, 62.5, and 12.5 nM. Note: High point may not be achievable depending on lot received.
  3. Prepare the activator mixture by combining equal volumes of 2 mg/mL Cytochrome C and 10 mM dATP for working concentrations of 1 mg/mL and 5 mM, respectively.
  4. Prepare reaction mixtures in tubes by combining 10 μL of each rhcIAP-1 curve dilution, 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture. Also, prepare the following controls:
    1. Total Control: 10 μL of Extraction Buffer, 10 μL of cell extract supernatant, and 5 μL of the cytochrome C/dATP activator mixture.
    2. Inactive Control: 15 μL of Extraction Buffer and 10 μL of cell extract supernatant.  The total reaction volume is 25 μL.
  5. Incubate for 60 minutes at 30 °C.
  6. After incubation, add 100 μL of Assay Buffer to each vial for a 1/5 dilution. Mix briefly.
  7. Dilute Substrate to 100 μM in Assay Buffer.
  8. In a plate load 50 μL of diluted incubated reaction mixtures, and start the reaction by adding 50 μL of 100 μM Substrate.
  9. Read at excitation and emission wavelengths of 400 nm and 505 nm, respectively, in kinetic mode for 5 minutes.
  10. Derive the 50% inhibiting concentration (IC50) of rhcIAP-1 by plotting normalized activity vs. reaction concentration of rhcIAP-1 (step 4) with Semi-Log Fitting [y = A + B * Log(x)].  Solve for x when y = 50.
  11. Normalized activity may be determined using the following equation:
  12.      % Normalized Activity = Sample (RFU/min) - Inactive Control** (RFU/min) x 100%
    Total Control (RFU/min)
Per Reaction:
  • rhcIAP-1 curve:  2000, 800, 400, 200, 100, 50, 25, and 5 nM
  • Substrate: 50 μM

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human cIAP-1 (HIAP-2) Protein, CF

  • API1Hiap-2
  • apoptosis inhibitor 1
  • baculoviral IAP repeat containing 2
  • baculoviral IAP repeat-containing 2
  • baculoviral IAP repeat-containing protein 2
  • BIRC2
  • cIAP1
  • c-IAP1
  • cIAP-1
  • hIAP2
  • HIAP-2
  • IAP homolog B
  • IAP2
  • IAP-2
  • Inhibitor of apoptosis protein 2
  • MIHB
  • MIHBHIAP2
  • NFR2-TRAF signalling complex protein
  • RING finger protein 48
  • RNF48hiap-2
  • TNFR2-TRAF-signaling complex protein 2

Background

cIAP-1 (also known as MIHB and HIAP-2) is a member of the inhibitor of apoptosis (IAP) family of proteins that inhibit the proteolytic activity of mature caspases. cIAP-1 has 3 BIR (baculovirus inhibitor of apoptosis) domains, a RING finger domain, and a caspase recruitment domain (CARD). cIAP-1 inhibits caspases by interaction of the BIR domain with the active caspase. Caspase activity may be restored through interactions with the Reaper like motif on mitochondrial proteins such as SMAC/Diablo or HTRA-2/Omi. cIAP-1 is reported to be cleaved by caspases in fetal rat hepatocytes treated with TGF-beta .

  1. Roy, N. et al. (1997) EMBO J. 23:6914.
  2. Deveraux, Q. et al. (1997) Nature 388:300.
  3. Deveraux, Q. and J. Reed (1999) Genes & Develop. 13:239.
  4. Herrera, B. et al. (2002) FEBS Letters 520:93.

Customers Who Viewed This Item Also Viewed...

AF8171
Species: Hu
Applications: IHC, Simple Western, WB
AF8221
Species: Hu, Mu, Rt
Applications: IHC, KO, Simple Western, WB
NB100-56583
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
NBP3-25355
Species: Dr, Hu, Mu
Applications: IHC, IHC-P, WB
AF4670
Species: Hu
Applications: CyTOF-ready, Flow, IHC, KO, Neut, WB
NBP2-33680
Species: Hu
Applications: IHC, IHC-P
NBP2-14214
Species: Hu
Applications: IHC, IHC-P
NB100-56311
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
NB100-56173
Species: Hu
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
NB500-201
Species: Ca, Fe, Gp, Ha, Hu, Mu, Rt
Applications: ChIP, Dual ISH-IHC, ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KD, Simple Western, WB
NB100-56104
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-Fr, IHC-P, IP, WB
NB100-56098
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-P, IP, WB
NB100-56144
Species: Hu, Mu, Rt
Applications: IHC, IHC-P, IP, WB
NB100-56116
Species: Ma, Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Simple Western, WB
NB100-56170
Species: Bv, Ca, Hu
Applications: IHC, IHC-P, IP, WB
NBP2-29661
Species: Hu, Mu, Rt
Applications: ELISA
375-TL
Species: Hu
Applications: BA
818-IA
Species: Hu
Applications: Inhibition Activity

Publications for cIAP-1/HIAP-2 (818-IA)(6)

We have publications tested in 2 confirmed species: Human, Bacteria - E. Coli.

We have publications tested in 3 applications: Bioassay, Surface Plasmon Resonance, Western Blot.


Filter By Application
Bioassay
(4)
Surface Plasmon Resonance
(1)
Western Blot
(1)
All Applications
Filter By Species
Human
(4)
Bacteria - E. Coli
(1)
All Species
Showing Publications 1 - 6 of 6.
Publications using 818-IA Applications Species
V Glorian, J Allègre, J Berthelet, B Dumetier, PM Boutanquoi, N Droin, C Kayaci, J Cartier, S Gemble, G Marcion, D Gonzalez, R Boidot, C Garrido, O Michaud, E Solary, L Dubrez DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues Cell Death Dis, 2017-05-25;8(5):e2816. 2017-05-25 [PMID: 28542143] (Bioassay, Bacteria - E. Coli, Human) Bioassay Bacteria - E. Coli, Human
Lee E, Seong D, Seo J, Jeong M, Lee H, Song J USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics. Cell Death Differ, 2015-01-23;22(9):1463-76. 2015-01-23 [PMID: 25613375] (Bioassay, Human) Bioassay Human
Guicciardi , Maria Eu, Werneburg , Nathan W, Bronk , Steven F, Franke , Adrian, Yagita , Hideo, Thomas , Gary, Gores , Gregory Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. PLoS ONE, 2014-03-14;9(3):e92124. 2014-03-14 [PMID: 24633224] (Bioassay) Bioassay
Oberoi-Khanuja , Tripat K, Karreman , Christia, Larisch , Sarit, Rapp , Ulf R, Rajalingam , Krishnar Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration. J Biol Chem, 2012-06-18;287(34):28445-55. 2012-06-18 [PMID: 22711539] (Bioassay, Human) Bioassay Human
Sekine K, Takubo K, Kikuchi R, Nishimoto M, Kitagawa M, Abe F, Nishikawa K, Tsuruo T, Naito M Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem., 2008-01-29;283(14):8961-8. 2008-01-29 [PMID: 18230607] (Surface Plasmon Resonance, Human) Surface Plasmon Resonance Human
Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD, Cooper G, Tuxworth WJ, Kuppuswamy D Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell. Cardiol., 2006-08-22;41(4):669-79. 2006-08-22 [PMID: 16928382] (Western Blot) Western Blot

Reviews for cIAP-1/HIAP-2 (818-IA) (0)

There are no reviews for cIAP-1/HIAP-2 (818-IA). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for cIAP-1/HIAP-2 (818-IA) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional cIAP-1/HIAP-2 Products

Blogs on cIAP-1/HIAP-2.


  Read full blog post.

cIAP1 - An apoptotic regulator with implications in drug resistant cancers
Cellular inhibitor of apoptosis protein-1 (cIAP-1) is an anti-apoptotic protein that is able to bind to caspases and inhibit their activity. Additionally cIAP-1 contains a RING domain with E3 ubiquitin ligase activity that is able to mediate the r...  Read full blog post.

Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human cIAP-1 (HIAP-2) Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol BIRC2
Uniprot